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Abstract  
BACKGROUND: Non-small cell lung cancer (NSCLC) is an insidious metastasis condition of the lungs often 
presenting no symptoms at the onset. Defining markers for quick determination of prognosis is essential for 
building up a treatment strategy. 
AIM: The aim of this study is to define the role of the Neutrophils-to-Lymphocytes ratio (NLR) and Platelets-to- 
Lymphocytes ratio (PLR) as biomarkers in patients with NSCLC, according to the stage and prognosis of the 
disease. 
METHODS: We investigated 20 patients with NSCLC. NLR and PLR are calculated and are evaluated according 
to the presence or absence of metastasis, stage of the disease, histological type and survival rate. 
RESULTS: We found that thirteen of the patients had low NLR, while the rest 7 had high NLR (mean 3.15). By 
analysing PLR we found that 11 patients have low and 9 have high level of PLR (mean 1.42). After the 
correlations have been made we discovered that in 90.1% of the patients with low PLR no lymph metastasises 
were detected, while in 50% of the patients with high PLR lymph metastasises were observed (2 = 3.99; P = 
0.046). We also discovered that in 84.6% of the patients with low NLR lymph metastases were absent, while in 
42.9% with high NLR lymph metastasises were present ( 2 = 1.83; P = 0.176). 
CONCLUSION: In conclusion, NLR and PLR were discovered as prominent biomarkers which provide relatively 
fast determination for prognosis in patients with NSCLC. 
 
 
 
 
 
Introduction 
 
Lung cancer (LC) is one of the leading causes 
of cancer related mortality [1]. Non-small cell lung 
cancer (NSCLC) accounts almost 85% of all LCs, 
while small cell lung cancer (SCLC) accounts nearly 
13% [1]. There are many prognostic factors that are 
associated with development and progression of LC: 
TNM status, age, stage, performance, gender, 
histological variant, serum levels of lactate 
dehydrogenase LDH, carcinoembryonic antigen CEA 
and others [2] [3] [4] [5]. Some newer biomarkers like 
epidermal growth factor receptor EGFR mutations and 
anaplastic lymphoma kinase ALK rearrangements 
provide useful information for determining the 
prognosis and building up a treatment strategy. 
Unfortunately, these tests are expensive, they can 
only be evaluated in a small subset of patients and the 
results take time [6] [7]. 
The validation of new biomarkers could ease 
the stratification of high risk patients and could also 
help make more accurate treatment plan. The relation 
between the immune response of the patients and the 
progression and prognosis of the neoplasms is 
confirmed by multiple analyses [8] [9]. It is known that 
the tumor microenvironment, which is conditioned by 
the immune response of the patient and also by the 
cancer itself, plays a crucial role in the processes of 
angiogenesis, metastasis and proliferation of the 
cancer cells [10]. Very important role of the 
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development of these processes is given to the cells 
of the extracellular matrix, the cells of the connective 
tissue and especially to cells such as: lymphocytes, 
neutrophils, macrophages, dendritic cells, platelets 
and others.  
Lymphocytes are the main cells of the 
antitumor immune response. Their antitumor 
capabilities are carried out by cytotoxic T-lymphocytes 
[11]. The tumor cells are vanished by cytolytic 
reactions or by induction of apoptosis via membrane 
receptor of the programmed death. To be effective, 
the antitumor response requires antigen presentation 
from the tumor cells or from the antigen presenting 
cells like macrophages and dendritic cells [12]. 
Antitumor capabilities of the lymphocytes are 
ineffective in clinically detectable cancer and are 
inversely proportional to the tumor size [13]. The cells 
of the NSCLC escape these immune mechanisms by 
expression of unstable or bad presented antigens as 
result of genetic or epigenetic mutations in course of 
oncogenesis [14].  
Neutrophils play main role in the processes of 
inflammation or antibacterial defense. Chronic 
inflammation is an established factor that increases 
the risk of cancer development. Examples are 
hepatitis B and the inflammatory bowel diseases, 
which could lead to development of hepatocellular and 
colorectal carcinoma respectively [15] [16]. The 
neutrophils take place in the processes of 
angiogenesis by secretion of pro-angiogenic factors. 
They directly affect the tumor progression by 
proteolytic release of epidermal growth factor, 
transforming growth factor beta and platelet derived 
growth factor [17]. Furthermore, neutrophils have the 
capability to influence other tumor promoting cells as 
T-lymphocytes and NK-cells [18]. Neutrophils have 
also direct or antibody dependent cytotoxic effect on 
the cancer cells [17]. It is known that there is 
neutrophilic polarization, which is caused by different 
cytokines (TGF-beta, INFs). Polarization defines the 
development of subpopulations of neutrophils that 
have antitumor properties as well as subpopulations 
that support the tumor progression [19]. A high 
number of neutrophils favor the prognosis according 
to a number of studies and exactly the opposite effect 
according to others [20]. 
Thrombocytes have central place in the 
processes of growth, progression and metastasis of 
neoplasms [21]. A hyper coagulation is related to 
more aggressive cancer disease and even more to 
thromboembolism, which in turn is one of the leading 
causes of death in patients with cancer [22] [23]. 
Platelets release many factors as PDGF, 
thrombospondin and thrombocytic factor 4 (which 
favor the hematogenic cancer spread), the adhesion 
of the tumor cells, invasion, the angiogenesis and in 
that way the tumor progresses. The prognostic 
significance of the platelets count in subsets of 
patients with NSCLC is known for a long time but it 
has unknown correlation [24] [25] [26] [27] [28]. 
Many inflammatory indicators attract attention 
because of their accessibility and prognostic efficacy 
when determining the prognosis in cancer patients. 
Such indicators are Neutrophil-to-Lymphocyte ratio 
(NLR) and Platelets-to-Lymphocyte ratio (PLR). The 
NLR is an important marker of systemic inflammation. 
Neutrophils, T- and B-lymphocytes have central role in 
the antitumor immune response [29]. The disturbance 
of the normal NLR is considered to be a consequence 
of the tumor related hypoxia and/or necrosis and is 
associated with anti- apoptosis effect [30]. The NLR is 
proven as a prognostic biomarker for determination of 
the prognosis of patients with different kind of cancer, 
including colorectal, breast cancer, gastric cancer, 
pancreatic cancer and esophageal cancer [31] [32] 
[33] [34] [35]. Many studies try to define the exact 
place of NLR as a prognostic biomarker in patients 
with NSCLC. The known evidences show unstable 
and discrepant results [36]. The prognostic value of 
the PLR is also associated with some kinds of cancer 
including gastric, breast, colorectal cancer and 
NSCLC [37] [38] [39] [40]. The prognostic value of 
PLR for determining the prognosis of patients with 
NSCLC is contrary [40] [41]. According to some 
authors, the high PLR has a negative prognostic 
value, while others do not succeed to establish clear 
correlation between prognosis and PLR [42] [43]. 
The objective of this study is to define the role 
of the NLR and PLR as biomarkers in patients with 
NSCLC, according to the stage and prognosis of the 
disease. 
 
 
Materials and Methods 
 
This is a retrospective analysis of NLR and 
PLR in patients with NSCLC at the time of diagnosis 
and before treatment. Twenty (20) patients with 
NSCLC were sampled between 2007 and 2016. Their 
respective NLR and PLR were calculated and 
evaluated accordingly with emphasis on the presence 
or absence of metastasis, stage of the disease, 
histological variants and survival. 
NLR and PLR are calculated and are 
evaluated according to the presence or absence of 
metastasis, stage of the disease, histological variant 
and survival. 
The study participants comprise of 19 men 
and 1 woman aged 24 to 75 years (mean 60.7 ± 11.9 
years). The patients were initially operated in the 
thoracic surgery clinic in Stara Zagora between 2007 
and 2016. Fifteen percent (15.0%) of the patients 
were diagnosed in stage T1 and T2; 75% in T3 and 
T4; lymphatic metastasises were detected in 5 
patients; distant metastasises were found in 4 patients 
(20%). Lung adenocarcinoma was diagnosed in 7 
patients, the other 13 patients were diagnosed with 
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squamous cell lung cancer.  
 
The Statistical Package for the Social 
Sciences SPSS 16.0 program for Windows was used 
for statistical analysis. The descriptive statistical tests, 
including the mean, standard deviation, and median, 
were calculated according to the standard methods. 
The frequency of distribution of NLR and PLR and the 
clinico-pathological parameters in 2x2 contingency 
tables was analyzed by 2-test. For all statistical 
analysis, p < 0.05 was considered to be statistically 
significant. 
The study was approved by the local Ethical 
Committee. 
 
 
Results 
 
Thirteen of the patients had low NLR, while 
the rest 7 had high NLR (mean 3.15). By analyzing 
PLR we found that 11 patients have low and 9 have 
high level of PLR (mean 1.42). After the correlation 
has been made we found that in 90.1% of the patients 
with low PLR no lymph metastases were detected, 
while in 50% of the patients with high PLR lymph 
metastasizes were observed (2 = 3.99; P = 0.046). In 
84.6% of the patients with low NLR lymph 
metastasizes were absent, while in 42.9% with high 
NLR lymph metastasizes were present (2 = 1.83; P = 
0.176) (Table 1). 
Table 1: Correlations between NLR, PLR and clinico-
morphological factors 
Parameter   NLR PLR 
  Low High р Low High р 
Age 
 
> 60.7 5 5  
0.515 
 
 
0.452 
 
 
0.948 
 
 
0.176 
 
 
0.482 
 
 
0.589 
6 
 
5 
 
10 
1 
 
2 
9 
 
10 
2 
 
10 
1 
 
4 
7 
4 
 
5 
 
9 
 
 
2 
7 
 
4 
4 
 
5 
3 
 
3 
6 
 
 
0.463 
 
 
0.381 
 
 
0.737 
 
 
0.046 
 
 
0.134 
 
 
0.599 
 
 
Sex 
 
 
Тumor (T) 
 
 
Nodulus (N) 
 
Мetastsasis 
(M) 
 
Histology type 
< 60.7 
 
М 
F 
 
Т1-2 
Т3-4 
 
N0 
N1-3 
 
M0 
M1 
 
Adenocarcinoma 
Squamous cell 
carcinoma  
7 
 
12 
1 
 
2 
11 
 
11 
2 
 
11 
2 
 
4 
9 
3 
 
7 
0 
 
1 
6 
 
4 
3 
 
5 
2 
 
3 
4 
 
 
 
Discussion 
 
The definition of prognosis is crucial for 
determination of the treatment strategy in patients with 
neoplasy. Many studies have tried to discover 
biomarkers, which could be used for defining the 
prognosis of patients with NSCLC [44]. The role of 
development and progression of cancers is the 
subject of research by many authors. The ratios NLR 
and PLR are very intensively investigated biomarkers. 
because of their accessibility and easy interpretation. 
The important place that NLR and PLR takes in the 
processes of cancerogenesis is evaluated by 
comparison of NLR and PLR in healthy persons 
compared to lung cancer patients. In one of the 
studies. significantly higher NLR and PLR are found in 
patients with LC (NLR: 4.42 vs 2.45. PLR: 245.1 vs 
148.2) [45]. 
Our data gained from the small group of 
patients show that higher NLR and PLR correlate with 
advanced disease and respectively worse prognosis. 
Similar results were observed in other studies 
involving more patients [41] [45] [46] [47] [48] [49]. 
Increased NLR and PLR calculated from 
peripheral blood samples are proved as independent 
predictive marker which is associated with worse 
prognosis in patients suffering from different kind of 
cancer including NSCLC [45]. Close to our results 
were seen in studies which evaluate cancers at 
different stages. These studies demonstrate that 
higher NLR and PLR are associated with worse 
outcome and advanced disease. Increased NLR and 
PLR determined at the time of diagnosis in non-
treated patients are associated with significantly 
worse survival in a study that includes 94 patients with 
NSCLC [50]. 
Even more interesting is the fact that the 
lower NLR and PLR are associated with better 
prognosis in patients with NSCLC. Our results show 
lower NLR and PLR in patients with no lymph 
metastasis and lack or in smaller degree distant 
metastasis. A similar conclusion was reported in 
earlier studies which investigated the combination of 
both NLR and PLR as prognostic biomarkers as one 
study that includes 366 patients with NSCLC in 
advanced stages. The patients were divided in three 
groups: worse prognosis NLR > 2.68 in the middle 
NLR < 2.68, PLR > 119.5 and better prognosis NLR < 
2.68, PLR < 119.5 [43]. 
It is observed that the NLR and PLR could 
change in course of therapy which supposes their 
estimation in each stage of treatment. In a study that 
evaluates the change of the values of NLR and PLR 
show that permanent elevated ratios are associated 
with worse prognosis and worse survival after 
treatment [51] [52] [53]. Despite. these observations 
the place of NLR and PLR is not fully defined. Some 
authors have not managed to find association of the 
prognosis and the value of NLR in patients with 
NSCLC [42]. Some data demonstrated lacks 
correlation between prognosis and the value of PLR in 
patients with NSCLC [43]. 
In conclusion, it can be noted that NLR and 
PLR are very accessible biomarkers and could be 
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very useful for relatively fast determination of the 
prognosis in patients with NSCLC. According to our 
data, only PLR can be used for prognosis 
determination, although very small subset of patients 
was investigated. Usually, higher NLR and PLR are 
associated with worse prognosis. Unfortunately, the 
reliability of these biomarkers is not well defined. More 
investigations are needed to clarify the place of these 
ratios as biomarkers.  
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